{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:18Z","timestamp":1786118838566,"version":"build-2736575974"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1097\/cco.0b013e3282c9ad65","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T03:04:46Z","timestamp":1186369486000},"page":"425-432","source":"Crossref","is-referenced-by-count":6,"title":["Maintenance therapy for low-grade lymphomas: has the time come?"],"prefix":"10.1097","volume":"19","author":[{"given":"Guillaume","family":"Cartron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Solal-C\u00e9ligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/jco.2006.24.18_suppl.7508","article-title":"Update of the FL2000 randomized trial combining rituximab to CHVP\u2013interferon in follicular lymphoma (FL) patients","volume":"24","author":"Foussard","year":"2006","journal-title":"J Clin Oncol"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V108.11.484.484","article-title":"Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma \u2013 4 years follow-up results of a phase III trial of the East German Study Group Hematology and Oncology (OSHO#39)","volume":"108","author":"Herold","year":"2006","journal-title":"Blood"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V108.11.481.481","article-title":"MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisone (R-CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL)","volume":"108","author":"Marcus","year":"2006","journal-title":"Blood"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/blood.V108.11.482.482","article-title":"Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma \u2013 results of a prospective randomized trial of the Gerlan Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior outcome in advanced follicular lymphoma: results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B","volume":"106","author":"Hochster","year":"2005","journal-title":"Blood"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma \u2013 a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"Van Oers","year":"2006","journal-title":"Blood"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/1097-0142(19870715)60:2<156::AID-CNCR2820600205>3.0.CO;2-K","article-title":"The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma","volume":"60","author":"Ezdinli","year":"1987","journal-title":"Cancer"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","article-title":"Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors","volume":"61","author":"Steward","year":"1988","journal-title":"Cancer"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood.V108.11.2479.2479","article-title":"A phase II trial of FM (oral fludarabine and mitoxantrone) chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for previously untreated follicular lymphoma patients","volume":"108","author":"Zinzani","year":"2006","journal-title":"Blood"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent nonhodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V104.11.747.747","article-title":"Rituximab given after high dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half of the patients with follicular non-Hodgkin's lymphoma: 36 months results of a multicenter open label phase II trial (M39012 trial)","volume":"104","author":"Morschhauser","year":"2004","journal-title":"Blood"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood.V108.11.2414.2414","article-title":"Quantitative assessment of circulating t(14;18) positive cells by RQ-PCR at diagnosis and follow-up correspond to clinical characteristics and predicts time to treatment failure in follicular lymphoma","volume":"108","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood.V108.11.2757.2757","article-title":"Prognostic significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients","volume":"108","author":"Hirt","year":"2006","journal-title":"Blood"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V108.11.325.325","article-title":"Clinical and molecular results of the multicenter randomized GITMO-IIL Trial in poor risk follicular lymphoma (FL) at diagnosis: rituximab-supplemented high-dose sequential chemotherapy (R-HDS) is superior to CHOP-R in molecular remissions rate, EFS and PFS","volume":"108","author":"Ladetto","year":"2006","journal-title":"Blood"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1182\/blood.V104.11.914.914","article-title":"High dose therapy\/ASCT with rituximab for in-vivo purging and post-ASCT consolidation in relapsed follicular lymphoma achived prolonged clinical and molecular remissions","volume":"104","author":"Woods","year":"2004","journal-title":"Blood"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan","year":"2005","journal-title":"J Clin Oncol"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R41-2-20210128","first-page":"448","article-title":"HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leuchemia. Early results from an ongoing phase I\/II clinical trial","volume":"108","author":"Coiffier","year":"2006","journal-title":"Blood"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood.V108.11.229.229","article-title":"Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction","volume":"108","author":"Umana","year":"2006","journal-title":"Blood"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.176.1.346","article-title":"An engineered human IgG1 antibody with longer serum half-life","volume":"176","author":"Hinton","year":"2006","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0145-2126(06)80004-4","article-title":"Safety of rituximab maintenance therapy in follicular lymphomas","volume":"30","author":"Solal-Celigny","year":"2006","journal-title":"Leuk Res"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"key":"R50-2-20210128","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"Van der Kolk","year":"2002","journal-title":"Blood"},{"key":"R51-2-20210128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2257.2001.00397.x","article-title":"Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post Rituximab and autologous stem cell transplantation","volume":"23","author":"McIlwaine","year":"2001","journal-title":"Clin Lab Haematol"},{"key":"R52-2-20210128","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2002-04-1271","article-title":"Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody","volume":"100","author":"Matteucci","year":"2002","journal-title":"Blood"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1086\/345746","article-title":"Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment","volume":"36","author":"Quartier","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R54-2-20210128","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","article-title":"Fatal reactivation of cytomegalovirus infection after use of rituximab for a posttransplantation lymphoproliferative disorder","volume":"13","author":"Suzan","year":"2001","journal-title":"N Engl J Med"},{"key":"R55-2-20210128","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V99.4.1486","article-title":"Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab","volume":"99","author":"Goldberg","year":"2002","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e3282c9ad65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:03Z","timestamp":1786035303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200709000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3282c9ad65","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}